U.S. flag An official website of the United States government
  1. Home
  2. Vaccines, Blood & Biologics
  3. News & Events (Biologics)
  4. What’s New for Biologics
  1. News & Events (Biologics)

What’s New for Biologics

Latest news from the Center for Biologics and Evaluation at FDA.

Items related to biologics will be added to the top of the list as they are posted on the site.

2/3/2022 January 30, 2022 Summary Basis for Regulatory Action - SPIKEVAX
2/3/2022 RegenMedEd Webinar: The Critical Role of Patients in Advancing Gene Therapy Treatments for Rare Diseases
2/2/2022 Q&A for Comirnaty (COVID-19 Vaccine mRNA)
2/2/2022 Q&A for Spikevax (COVID-19 Vaccine mRNA)
2/02/2022 Vaccines and Related Biological Products Advisory Committee February 15, 2022 Meeting Announcement
2/1/2022 Complete List of Licensed Products and Establishments
2/1/2022 Complete List of Substantially Equivalent 510(k) Device Applications
2/1/2022 Complete List of Currently Approved Premarket Approvals (PMAs)
2/1/2022 Complete List of Currently Approved NDA and ANDA Application Submissions
2/1/2022 BK210652 - BD Stem Cell Enumeration Kit
1/31/2022 January 24, 2022 Clinical Memorandum - YESCARTA
1/31/2022 January 28, 2022 Approval Letter - cobas TaqScreen MPX Test, version 2.0
1/31/2022 January 31, 2022 Approval Letter - SPIKEVAX
1/31/2022 January 28, 2022 Approval Letter - VONVENDI
1/31/2022 January 28, 2022 Approval Letter - Alere Determine HIV-1/2 Ag/Ab Combo
1/28/2022 Vaccines and Related Biological Products Advisory Committee March 3, 2022 Meeting Announcement
1/27/2022 January 25, 2022 Approval Letter - YESCARTA
1/26/2022 Premarket Approval (PMA) for CBER-Regulated Products
1/24/2022 Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2022
1/24/2022 BK210649 - BD Vacutainer ACD A Blood Collection Tube; BD Vacutainer ACD B Blood Collection Tube
1/20/2022 Patient Engagement & Regenerative Medicine: An FDA CBER Workshop for Patient Advocates
1/18/2022 Frequently Asked Questions (FAQs): Electronic Submissions Program for CBER-Regulated Products
1/18/2022 Premarket Notification 510(k) Process for CBER-Regulated Products
1/14/2022 Clinical Investigator Status (Biologics)
1/14/2022 2021 Biological Device Application Approvals
1/13/2022 CBER Vacancy: Staff Fellow - Pharmacology/Toxicology Reviewer
1/11/2022 Exceptions and Alternative Procedures Approved Under 21 CFR 640.120(a)
1/11/2022 Updated Information for Blood Establishments Regarding the COVID-19 Pandemic and Blood Donation
1/10/2022 Recommendations for Investigational COVID-19 Convalescent Plasma
1/10/2022 eSubmitter Application History
1/7/2022 Investigational COVID-19 Convalescent Plasma; Guidance for Industry
1/7/2022 January 6, 2022 Approval Letter - BEXSERO
1/6/2022 Cumulative CBER Regenerative Medicine Advanced Therapy (RMAT) Designation Requests Received by Fiscal Year
1/6/2022 CBER Regenerative Medicine Advanced Therapy (RMAT) Approvals
1/6/2022 CBER Regenerative Medicine Advanced Therapy (RMAT) Designations Withdrawn after Granting or Rescinded by Fiscal Year

 



Back to Top